We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.
On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies.
We continuously seek to understand the diverse perspectives of rare patients to courageously forge new paths that can make a difference in their lives and provide hope for today and tomorrow.
We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub.
We are dedicated to staying informed and engaged on topics that may impact the rare disease community, featuring community members and sharing what we learn. Find info at our Pathfinder.
April 1, 2020 — The April edition of PharmaVOICE magazine features our CEO Eric Dube, Ph.D., along with other members of the PharmaVOICE 100 leadership community on their top priorities for the remainder of 2021 and the leadership skills that helped guide them through the pandemic.
Hear from Christopher as he describes his journey with focal segmental glomerulosclerosis (FSGS), from diagnosis and day-to-day with this rare kidney disease, to his work with NephCure Kidney International.
SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2020 financial results and provided a corporate update.
“How do you know you have IgA nephropathy?” asked Gisela’s nephrologist skeptically. Gisela was 30 years old, talking to a nephrologist for the first time in a decade. Read and watch her story.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Genes, and rare disease advocates and patients worldwide in recognizing February 28 as Rare Disease Day 2021.
Retrophin is now Travere Therapeutics.
© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Rare Disease Diversity Coalition Publishes Roadmap to Achieving Health Equity in Rare Disease
NewsOn February 26, 2021, Travere Therapeutics was honored to have Linda Goler Blount, president of the Black Women’s Health Imperative (BWHI), present a keynote address at our Rare Disease Day program. The opportunity for Travere team members to hear Linda speak came on the heels of the first meeting of the Rare Disease Diversity Coalition, which is led by BWHI. Read more>